International Journal of Scientific Research in Engineering and Management (IJSREM)
Volume: 09 Issue: 11 | Nov - 2025 SJIF Rating: 8.586 ISSN: 2582-3930

Review on Formulation Development: Mucolytic and Expectorant in Pediatric Wet cough.

Sayali Dadasaheb kardile, Jaydeep Babasaheb Pawar Corresponding author, Kardile Sayali Dadasaheb

Swasthyadarpan, pratishthan's, Shantiniketan College of Pharmacy, A/P. Dhotre (B, K), Tal. Parner, Ahmednagar, Maharashtra- 414304, India.

Gmail: kardilesayali10@gmail.com

Abstract

Mucus hypersecretion is a clinical feature of severe respiratory diseases such as asthma, cystic fibrosis and chronic obstructive pulmonary disease. Airway mucosal infection and/or inflammation associated with these diseases often gives rise to inflammatory products, including neutrophil-derived DNA and filamentous actin, in addition to bacteria, apoptotic cells and cellular debris, that may collectively increase mucus production and viscosity. Coactive agents have been the medication of choice for the treatment of respiratory diseases in which mucus hypersecretion is a clinical complication. The main purpose of coactive drugs is to increase the ability to expectorate sputum and/or decrease mucus hypersecretion. Many coactive drugs are currently available and can be classified according to their putative mechanism of action. Coactive medications include expectorants, mucoregulators, mucolytics and microkinetic. By developing our understanding of the specific effects of coactive agents, we may result in improved therapeutic use of these drugs. The present review provides a summary of the most clin relevant coactive drugs in addition to potential mechanism of action.

In healthy individuals, mucus secretion is not excessive and mucus continuously removed by epithelial ciliated cells, then propelled towards the larynx for swallowing [1]. However, an increase in airway mucus secretion can be problematic, especially if the rate of secretion exceeds the rate at which it can be removed by normal ciliary action. Increased mucus secretion (hypersecretion) is a clinical feature of severe respiratory diseases, such as asthma, cystic fibrosis (CF) and chronic obstructive pulmonary disease (COPD). Typically, during infection and/or inflammation, the airway mucosa
responds by increasing the volume of mucus hat is secreted. This response is mainly due to hyperplasia and hypertrophy of goblet cells and the submucosal gland, a phenomenon recognized as secretory hyperresponsiveness [2]. The inflammatory process results in loss of cells and ciliary function, destruction of the surfactant layer by airway phospholipases and alteration of the biophysical properties of the mucus [3, 4]. In addition, by-products accumulated during the inflammatory process include neutrophil-derived DNA and filamentous actin (F-actin), dead/apoptotic cells, bacteria and cell debris. Collectively, these factors contribute to mucus purulence, and when expectorated, this mucus is termed sputum [5].

In healthy individuals, mucus secretion is not excessive and mucus continuously removed by epithelial ciliated cells, then propelled towards the larynx for swallowing [1]. However, an increase in airway mucus secretion can be problematic, especially if the rate of secretion exceeds the rate at which it can be removed by normal ciliary action. Increased mucus secretion (hypersecretion) is a clinical feature of severe respiratory diseases, such as asthma, cystic fibrosis (CF) and chronic obstructive pulmonary disease (COPD). Typically, during infection and/or inflammation, the airway mucosa
responds by increasing the volume of mucus hat is secreted. This response is mainly due to hyperplasia and hypertrophy of goblet cells and the submucosal gland, a phenomenon recognized as secretory hyperresponsiveness [2]. The inflammatory process results in loss of cells and ciliary function, destruction of the surfactant layer by airway phospholipases and alteration of the biophysical properties of the mucus [3, 4]. In addition, by-products accumulated during the inflammatory process include neutrophil-derived DNA and filamentous actin (F-actin), dead/apoptotic cells, bacteria and cell debris.
Collectively, these factors contribute to mucus purulence, and when expectorated, this mucus is termed sputum [5].

Keywords: - mucoactive agents, expectorants, COPD, cystic fibrosis, Chronic cough, microkinetic agent, mucolytic agent.

Introduction Mucolytics

Mucolytics are medications that decrease the thickness (viscosity) and breakdown mucus in the respiratory system making it easier to cough up and clear from the airway Ex: - Ambroxol Bromhexine

Expectorants

Expectorants is a medication that promotes the discharge or expulsion of mucus from. The respiratory tract by thinning and loosening it, making it easier to cough up from the lungs and airways.

Ex: - Guaifenesin, Honey.

Mucus hyperaccretion is a clinical feature of asthma, cystic fibrosis, and chronic obstructive pulmonary diseases Air ways mucosal infection and /or inflammation associated with these diseases often gives rise to inflammation

associated with this disease Often gives rise to inflammatory product including. Neutrophil derived DNA and inflammatory action its addition to bacteria, apoptotic Cell and Cellular debris that may collectively increase mucus production and viscosity[6].

mucoactive agents have been medication of choice for the treatment of respiratory disease in which mucus hypertension is a clinical complication. The main purpose of mucoactive drugs is to increase the ability to expectorant sputum and Oregon decrease mucus hypersecretion. Mucoactive medication include expectorants mucoregulators, Mucolytic and Microkinetic. In conditions like COPD and asthma chronic irritation of the Airways leads to mucus hypersecretion[7,8].

Advantages and disadvantages Mucolytics

Effective for severe conditions

Advantages of mucolytics: -

Highly effective for chronic respiratory disease like cystic fibrosis in (CF), Chronic Obstructive pulmonary disease (COPD) And bronchiectasis, where mucus is thick and sticky.

Disadvantages of Mucolytics: -

Requires a prescription and a direct delivery to the lungs via nebulizer for maximum effect, which less convenient than oral medications.

Breaks down Mucus directly

Advantages of Mucolytics: -

The active ingredient yen acetyl cysteine (NAC) Breaks down the disulfide bonds in the mucus proteins, and dornase alpha breaks down DNA in Purulent mucus Direct action provide powerful relief.

Disadvantages of mucolytics: -

Can cause side effects, including nausea, vomiting, stomach upset and skin rash. In some cases, it can cause more serious reactions like bronchospasms especially in patients with asthma.

Antioxidant and anti-inflammatory effects

Advantages of Mucolytics: -

The mucolytics s yen acetyl cysteine also has antioxidant and anti-inflammatory properties, offering additional benefits for patients with chronic lung inflammation.

Disadvantages of Mucolytics

Can worsen respiratory Distress, particularly in young children who may struggle to clear a newly thinned secretion.

Aids clearance of purulent secretion

Advantages of Mucolytics: -
For condition involving thick, infected mucus, Such as CF, Mucolytics that target DNA (Like Dornase Alfa are very useful)

Disadvantages of Mucolytics
Intravenous yen acetyl cysteine can trigger anaphylactic reactions, through this is rare.

Advantages and disadvantages of Expectorants
Over-the- Counter (OTC) availability

Advantages of Expectorant: -
The most common expectorant, Guaifenesin (Pound in Mucinex and Robitussin), is widely available over the counter, making it easy to access for treating common congestion.

Disadvantages of expectorant: -

Effectiveness is often debated and poorly researched, with some studies questioning its clinical benefits beyond the effects of staying hydrated

Effective for short term illness

Advantages of expectorant: -
Useful for congestion associated with common short-term illnesses, such as colds, the flu or acute bronchitis.

Disadvantages for expectorant: -
Not suitable for chronic coughs, which should be evaluated by a healthcare provider to rule out more serious causes like asthma or COPD.

Makes coughing more productive

Advantages for expectorant: -
By thinning secretions and adding moisture to the airways, expectorants help turn a dry, non-productive cough into a more effective one. This helps clear irritants and bacteria.

Disadvantages of expectorant: -
Can cause mild side effects like headache, and nausea, and vomiting. In combination products, the other ingredients may cause additional side effects.

Open used with other medications

Advantages of expectorant: -
The most common expectorants are generally considered safe and can be used in combination with other curve and cold medications.

Disadvantages of expectorant: -
Individuals with underlining health issues like kidney liver, or heart problems should use expectorant with caution and consult a

doctor.

Mucolytics common composition

This agent breaks down or loosens thick mucus in the Airways, making it easier to clear.

Active ingredient	Mechanism of action Hey Cortana
N acetylcysteine	Brakes disulfide bonds in mucus, reducing viscosity
Carbocation	mucus composition and reduce viscosity
Ambrosoli	stimulates surfactant production, mucolytics action.

Expectorant- common compositions

Theses agent increases the volume or hydration of airways secretion, helping expel mucus via coughing

Active ingredient	mechanism of action
Guaifenesin	increases respiratory tract fluid; decreases mucus adhesiveness Ammonium chloride irritates gastric mucous—reflex increase in bronchial secretion

Significance of mucolytics and expectorant

1. Aid in airways clearance

Boths classes help remove mucus from lungs and bronchi. This improves ventilation and reduces airways obstruction. Especially important in conditions where mucus is thick and difficult to expel, like:

Bronchitis Bronchiectasis Cystic fibrosis
Pneumonia (in some cases)
COPD (in older children or adolescents)

2. Reduce cough severity and frequency

By clearing secretions, these drugs can;

Lessen the irritation caused by mucus buildup Make coughing more productive and efficient Sometimes reduces night-time coughing in order children

3. improve comfort and quality of life

Children with wet cuffs often have chest conjugations difficulty sleeping, and fatigue. These agents can relieve the symptoms, make breathing and rest easier.

4. Prevent compensations of mucus stasis

Thick or retained mucus can lead to:
Secondary infections
Atelectasis (Collapsed lung segments) Worsening of chronic disease
Mucolytics especially in chronic condition help prevent these complications

5. Supportive roles in chronic respiratory disease

Mucolytics like young acetylcysteine or carbocisteine are often part of long-term therapy in; Cystic fibrosis
Primary ciliary dyskinesia Bronchiectasis
They enhance airway hygiene and red exacerbation frequency

Significance

1 Acute respiratory tract infection (RTIs)

Example; Acute bronchitis, Viral lower respiratory infection, Pneumonia (in recovery phase) Expectorants may help make curve more productive by hydrating secretions.

Mucolytics may reduce mucus thickness to ease Clearance.

2 Chronic respiratory diseases

Condition	Role of mucolytics/ Expectorant
Cystic fibrosis	Mucolytics like eon acetyl cysteine or Dornase alpha not a classic mucolytics help breakdown thick sticky mucus.
Bronchiectasis	Regular use of mucolytics example carbocisteine add chest physiotherapy help reduce mucus Statis.

3 Post infectious cough with residual mucus

After recovery from pneumonia or bronchiolitis, children may have lingering in wet cough due to mucus residue. Short term use of mucolytics and expectorant may help clear secretions through not always necessary.

4 Sinopulmonary condition

Examples; chronic sinusitis with Post nasal drip process media with effusion,

Mucolytics like carbocisteine sometimes used to reduce mucus viscosity in ENT condition. May help clear middle ear fluid or nasal mucus, through evidence in mixed.

5 Supportive use in Airways clearance techniques

In physiotherapy best based Airways clearance

(e.g., CF or bronchiectasis) mucolytics are used before chest physiotherapy or nebulization to facilitate mucus expulsion.

6 Nebulized formulation for inhalation

Nebulized N-acetylcysteine (NAC) used in hospital to manage thick secretion example in ventilated patients, severe pneumonia, asthma with mucus plugging.

7Age consideration and caution

Age of group	Application	Caution
<2 years	Rarely use	Risk of mucus retention, Airways obstruction
2-6 years	limited Use	Only clinically indicated

>6 years More common Especially in chronic ENT condition

Classification of mucolytic and expectorants

1. mucolytics

These agents break down the structure of mucus, making it less viscus and to expel.

A. True mucolytics

Act by breaking chemical bond in mucus. Acetylcysteine

Breaks disulfide bonds in mucoproteins

Also used as an antidote for acetaminophen overdose. Carbocisteine (carboxymethyl cysteines)

Modulates mucus viscosity and improves mucociliary clearance. Mensa (sodium 2-mercaptoethane sulfonate)

Used more often for cryoprotection but has mucolytic properties.

B. peptide mucolytics

Breaks down DNA / protein in purulent sputum. Dornase alfa (rhodanese)

Used in cystic fibrosis to break down extracellular DNA in mucus

2. Expectorant

These agents increase the volume or hydration of secretions, promoting easier removal through coughing

A. Direct Expectorants

Stimulate bronchial blends directly to increase mucus output Potassium iodide

Sodium citrate

B. Reflex expectorants

Irritate the gastric mucosa to stimulate vagal reflex, increasing respiratory tract Secretions. Guaifenesin (Most common OTC expectorant) Ipecacuanha (Low doses)

Parts/Components (The example of mucolytics): Drug name How it works

N- Acetylcysteine	Brakes disulfide bonds in mucus
NAC Proteins	
Carbocisteine	Reduce mucus viscosity can help its drainage
Bromhexine /ambroxol	Enhance mucus clearance and has anti-inflammatory effect

Function

Breaks down thick mucus in the lung's bronchi or trachea. Makes coughing more productive by loosening mucus.

Used in chronic respiratory disease like:

Chronic bronchitis

COPD chronic obstructive pulmonary disease Cystic fibrosis

May also have antioxidant properties e.g.; NAC

Parts/Components/ (Examples of expectorants)

Drug name	How it works
Guaifenesin	Increase mucus volume and reduces viscosity
Potassium iodide	Stimulates blends to secret thinner mucus
Water vapor	Natural expectorant that moistens Airways

Functions

Stimulate secretion of thinner mucus from the respiratory tract lining Help clear mucus from the Airways by making coughing more effective. Often used for productive coughs in condition like;

Common cold Acute bronchitis
Mid respiratory infections

Introduction to **Ambroxol**

Ambraxol is a mucolytic agent commonly used to treat respiratory conditions associated with excessive or thick mucus. It is metabolite of bromhexine with a more potent and direct effect on thinning mucus and improving its clearance from the respiratory tract [9].

Ambroxol work by breaking down the structure of mucus, making it less sticky and easier to expel through coughing. It also stimulates the surfactant production and enhances the ciliary activity which helps to move mucus of the lungs and Airways.

Due to its expectorant, anti-inflammatory, and mid local anesthetic properties, Ambroxol is widely used in the management of;

Productive weight cough

Acute and chronic bronchitis, Chronic obstructive pulmonary disease COPD[10].

Ambroxol-Detailed drug information

Generic name: - Ambroxol hydrochloride

Drug class: - Mucolytic agent (also has mild local anesthetic and anti-inflammatory properties) Common brand names: - Mucosolvan, Ambrolex , Losolven , AmbrodilBroxol Mechanism of action

Stimulate surfactant production and activities Ciliary motility, enhancing mucociliary clearance. Breaks down mucus viscosity, making it thinner and easier to expel via coughing.

Has antioxidant and local anesthetic effects, which may help reduce throat irritation and pain during cough[11].

Indications (Uses)

Condition	Use
Acute and chronic	To clear thick mucus and is productive cough respiratory disease
Bronchitis (active/	Symptomatic relief Chronic)
Pneumonia	As in adjacent to help with mucus clearance
Bronchiectasis	Chronic management
Asthma (COPD in	Supportive in mucus clearance older children adult)

Pediatric Dosing (syrup)

Ambroxol syrup (15 mg/5 ml)

Children two to five years: 1.25 ML to 2.5 ML Two to three times daily Children 6 to 12 yrs 5ML two to three times daily

Children >12 years and adults :10ML three times daily

Other formulations

Syrup

Drop for infants Nebulizer solution

Injectable (for hospital use) Lozenges (for sore throat relief)

Onset and duration

On set with 30 minutes oral Duration of action ~6-12 hours

Types of ambroxol

1 Ambroxol syrup/ Oral suspension Use mainly for children or adults Who prefer Easy to swallow

Typically available in different concentrations e.g.; 15ml/5ml

2 ambroxol tablets /capsules

Available in immediate release for sustained release forms Convenient for adults

Usually comes in doses like 30MG or 75MG

3 Ambroxol drops

Concentrated liquid forms

Often used for children who have difficulty swallowing syrup or tablets

4 Ambroxol inhalation solution

Use in nebulizers

Direct delivery to the lungs

Effective for acute chronic respiratory disease with mucus retention

5 Ambroxol lozenges

Throat lozenges containing ambroxol

Used for smoothing irritated throat and easing cough

7 Ambroxol injectable

Registered via injection or infusion

Contraindication

Hypersensitivity to Ambraxol

A caution in Gastric ulcer Disease

Non recommended infants under six months without medical supervision

Precautions

Renal or Hepatic impairment: use with caution

Pregnancy use only if clearly needed (especially in first trimester) Location: precise into breast milk in small amounts; caution advised

Drug interaction

No significant interactions with commonly used medications

May increase penetration of antibiotics Example amoxicillin, Cefuroxime into bronchial secretion sometimes considered beneficial

Storage

Store below 25°C

Keep out of reach of children Protect from light and moisture

Clinical notes

Works best when taken with plenty of fluids, which aids mucolytic action

Often combined into syrup with bronchodilator example: -Salbutamol, terbutaline, or expectorant example: - guaifenesin In lozenges, from it can help relief sore throat pain due to local anesthetic effect

Introduction to **guaifenesin**

Guaifenesin I commonly used expectorant that helps manage productive (wet) cough by making mucus in that airway thinner and easier to expel. It works by increasing the volume and reducing the viscosity of respiratory tract secretions, which facilitates mucociliary clearance [12].

Originally derived from guaiac tree resin, guaifenesin has been widely used for decades and is especially effective in condition involving chest congestion and thick phlegm, such as;
Acute bronchitis
Upper respiratory tract infections, Common cold with chesty cough, Chronic bronchitis[13].
Guaifenesin- detailed drug information Generic name
(also known as glyceryl guaiacol ate)
Drug class
Expectorant (microkinetic agent)

Common brand names
Benylin expectorant Robitussin
Tixylix Mucinex
Corex expectorant

Mechanism of action
Guaifenesin acts by
Increasing the volume and reducing the viscosity of bronchial secretion.
Irritating the gastric mucosa mildly, which stimulates the vagal reflex, increasing respiratory tract fluid production. This results in easier expectoration (coughing up) of mucus, making the cough more productive.
It does not suppress the cough reflux, unlike antitussives [14].

Indications (therapeutic uses)

Condition	purpose
Acute bronchitis	To, thin and loosen mucus
Productive (wet) cough	To, helps expel mucus more effectivity Common cold with chest Symptomatic relief
Congestions	
COPD (chronic bronchitis	Adjunct to help mucus clearance Post-infectious cough useful in lingering wet cough Sinusitis with post-nasal drip may help reduce mucus viscosity

Pediatric dosing as expectorant

Age	Typical dose in syrup
2-5 years	2.5-5 ML (Typically 50-100mg per dose Every 6-8 hours
6-12 years	5-10 ml every 6-8 hours
>12 Years and adults	10-15 every 6-8 hours

Other formulations
Syrup (most common)
Iv oral solution used for acid base imbalance, not cough Tablets (rarely used in modern practice)

Onset and duration
On set: ~30 Minutes (oral) Duration :4-6 hours

Types of guaifenesin
1 immediate-release guaifenesin
This is the standard form that starts working shortly after injections Usually available in liquid syrups, tablets, or capsules
Typically, those multiple times a day because it's metabolized relatively quickly.

2 extended-release (ER) guaifenesin Designed to release guaifenesin Slowly over times Usually come in tablet forms

Allow for less frequent dosing example every 1hours

3 combination products

Guaifenesin is often combined with other active ingredient for broader symptom relief: Guaifenesin + dextromethorphan (a cough suppressant)

Guaifenesin + Phenylephrine (a nasal decongestant) Guaifenesin + Acetaminophen (Pain relief fever reducer)

Others with antihistamines or additional cold and flu Symptoms relievers.

4 Liquid syrups and solutions

Often use for children are people who prefer liquid medications

Contraindication

Severe liver or kidney disease Metabolic or respiratory acidosis

Patients on sodium restricted diet, Hypersensitivity to ammonium salt

Precautions

Caution in children under two years (risk of mucus accumulation or choking) Use carefully in asthma or COPD -excessive secretions may worsen symptom Avoid overdose -higher doses may cause toxicity

Monitor in patients with electrolyte imbalance

Drug interaction

may interact with urinary alkalinizes (e.g. Sodium bicarbonate)

Use with caution alongside diuretics may affect electrolyte balance No significant interactions in standard low dose expectorant use

Storage

Store at room temperature 15 to 25°C Keep tightly closed

Clinical notes

Always taken with fluid to help thin mucus

Commonly used in multi-ingredient curve syrup, often with empty Antihistamine, bronchodilators, or decongestant. Not effective alone for chronic curve or severe mucus retention

Avoid prolongated or unsupervised Use, especially in young children.

Summary table

Parameter	Details
Drug class	Expectorant
Mechanism	Replace increase in bronchial secretion
Form Syrup often in combinations	
Pediatric use	Common in 2+ years age-appropriate dosing
Side effects	GI upset, Nausea, Rare CNS symptoms
Use infants	Not recommended under 2 years
Pregnancy / Lactation	Caution advice limited data

Clinical case example

A 4-year-old Presents with a wet, chesty cough for 4 days, no fever, normal appetite and cough syrup containing ammonium chloride + diphenhydramine +sodium citrates every 8 hours for 5 days, along with hydration saline nasal drops. Add flow -up the child shows reduce mucus thickness and cough frequency.

Introduction to **Carbocisteine**

Carbocisteine Also Known as carboxymethyl cysteine Is a mucolytic agent used to treat respiratory conditions where thick sticky mucus is a problem It works by breaking down the chemical bonds in the mucus reducing its viscosity and elasticity which makes it easier to cough up and clear from the lungs and Airways [14].

Carbocisteine He is commonly prescribed for:
Chronic bronchitis Productive (wet) cough
Chronic obstructive pulmonary disease (COPD) Sinusitis
Otitis media with effusion
Cystic fibrosis (as adjective therapy)
Unlike some other mucolytics carbocisteine Also help normalize mucus production not just team heat and it considered well tolerated in both children usually over two years adults.
It is available in syrup, capsule and tablet forms and is most effective when used with plenty of plenty and aids mucus clearance

Carbocisteine Detail drug information Generic name (Also known as carboxymethylcystin) Drug class Mucolytic agent

Common brand names:
Mucodyne Rhinathiol Solmux Bornklyn

Mechanism of action Carbocysteine

Words by modifying the structure of mucus it reduces the viscosity and elasticity of sputum by breaking down mucoprotein bonds. Promotes normalization of mucus secretion making it thinner and easier to expel. Help restore the functions of mucosillary transport, Adding in Airways clearance.
Unlike NAC it does not break disulphide bonds directly but alters mucin composition[14].

Therapeutic indications

Conditions	Use
Acute chronic bronchitis	Facilitates mucus clearance Productive wet cough Symptomatic relief
Chronic obstructive pulmonary disease	Reduces frequency and severity of Exhibition
Cystic fibrosis	adjunct to add sputum expectoration
Sinusitis And Otitis	Help reduce mucus statis Media with infusion
Post infections cough	short term use for mucus clearance

Pediatric dosing
Carbocisteine Syrup 250MG/5 ml/Or 125MG/5ML

Age group	Dose
2-5 Years	2.5 ML (125MG) 3 times daily (Max 750MG per day)

6-12	5ML (250MG) 3 times daily (Max 1500 EMG per day)		years
>12 years C syrup	750MG Dash 1500 EMG per day in divided doses	adults	capsule

Available formulations

Syrup commonly 125MG / 5ML or 250MG / 5ML Capsule (375MG, 500MG)
Tablets
Oral solution

Onset and duration

Onset; Within one to two hours of oral intake.
Duration: Where is affect last for several hours, hence dosed two to three times per day.

Types of carbocisteine

1 Immediate release carbocisteine
Available as syrups, Capsules, Tablets Starts working shortly after administration. Typically taken multiple times per day (example 3 times daily)

2 Extended-release ER carbocisteine Formulated to release the drug slowly overtime Usually available in capsule or tablet forms Allow for less frequent dosing (example two wise daily) Provides more consultant blood levels and symptoms control

3 Syrups and liquid suspensions
Often preferred for children or people who have difficulty swallowing tablets Dosage is major with a spoon or cup for accuracy

4 Combinations product
Sometimes carbocisteine is combined with other medicines, such as:
Carbocisteine + Cough suppressant (less common since carbocysteine helps clear mucus)

Contraindications

Hypersensitivity to carbocysteine or excipients Active Peptic Ulcer disease
Severe renal or hepatic impairment Children <2 years risk of mucus Retention

Precautions

Use with caution in patience with history of bleeding or ulcers. Monitor in patients with asthma or chronic lung disease.
Ensure adequate hydration to optimize mucolytic effect.

Drug interaction

Minimal clinically significant interaction
Can we safely, administered with antibiotics, bronchodilators, and corticosteroids first stop.
Avoid with anti-tissue cup suppressants may leads to mucus accumulation due to reduce cough reflex

Storage

Store at room temperature 15 to 25°C Project from moisture and direct sunlight

Clinical notes

Best taken with plenty of flutes to assist mucus thinning. May take a few days to show full effect in chronic cases
Use regularly in chronic Bronchitis COPD and ENT infections with thick secretions.

Often preferred Over yen N-acetylcysteine in children due to better taste and GI tolerance

Summary table

Parameters	Details
Drug class	Mucolytics
Mechanism	Reduces mucus viscosity by altering mucoprotein
Indications	Wet cough, Bronchitis, COPD, sinusitis
Onset One to two hours	
Common dose	250 to 1500 MG per day age dependent
Formulation	Syrup, capsule, tablet
Side effects	GI upset, rash, rarely bleeding
Age restriction	Not for <2 years

Clinical case example

Oh 7-year-old child presents with a wet persistent add nasal congestion after a viral infection. Examination reveals post nasal drip and thick mucus on throat exam. The Dr Prescribe.
Carbocisteine 250M Purify ML syrup 5ML 3 times a day Saline nasal drops, steam inhalation, and hydration Follow up after 5 days show
Thinner mucus
Reduced coughing spell No adverse effect

Introduction **ammonium chloride**

Ammonium chloride is a traditional expectorant commonly used in combination curve syrups to treat productive (wet) cough. It works by irritating the gastric mucosa, which reflexively stimulates the bronchial glands to increase respiratory secretions, thereby helping the loosen and expel mucus from the air ways [15].
Through rarely use alone, ammonium chloride is often found in multi-ingredient formulations with antihistamines, decongestants, bronchodilators or other expectorant like guaifenesin.
In addition to its respiratory use at higher doses ammonium chloride also functions as systemic acidifier and has been used in the treatment of metabolic alkalosis and two acidify urine [16].
Because of its mechanism, it is most effective when combined with adequate fluid intake and is not recommended for use in infants under two years due to the risk of mucus retention [17,18].

Ammonium chloride detailed drug information

Generic name: - Ammonium chloride
Drug class: - Expectorant (at low doses)
Systemic acidifier at higher doses used in different clinical contexts

Common brand combinations

Ammonium chloride is rarely used alone as a drug. It, key found in combination cough syrups with other agents like: Diphenhydramine
Guaifenesin Phenylephrine Terbutaline
Example combination products Corix
Tixylix Benadryl

Mechanism of action (as an expectorant)

Text by Pittie irritating the gastric mucosa, which triggers a reflex stimulation of bronchial glands via the vague nerve. This leads to increased respiratory tract secretions, making mucus thinner and easier to expel [19].

Indications (in respiratory use)

Condition	Purpose
Wet / Productive cough	to assist in mucus clearance Acute bronchitis Adjunct to relief congestion
Upper respiratory tract infection (URTIs)	in combination with antihistamines or decongestant
Post nasal drip or sinusitis	Help Thin secretion
Bronchitis with thick sputum	Expectorant effect in combination syrup

Pediatric dosing (as expectorant);

Age group	Typical dose in syrup
2 to 5 years	2.5 2 5ML Typically 15 to 100 MG per dose every 6 to 8 hours
6 to 12 years	5 to 10ML every 6 to 8 hours
>12 years and adults	10 to 15ML every 6 to 8 hours

Other formulations:
Syrup (most common)
Iv or oral solution used for acid base imbalance not cough Tablets (Rarely used in modern practice)

Onset and duration
Onset~30 minutes (oral) Duration: 4 to 6 hours

Types of ammonium chloride
1 Industrial grade ammonium chloride
Used mainly in manufacturing such as in fertilizers batteries metalwork like shouldering and metal cleaning and pharmaceuticals
Usually less pure than food or pharmaceutical grades
May contain some impurities acceptable for industrial uses

2 Pharmaceutical grade ammonium chloride
High purity suitable for medical or pharmaceutical use
Use as an expectorant in cough medicine or to acidify the urine in certain medical treatments. Must meet strict quality standards.
3 Food grade ammonium chloride
Approved for use in food products as flavoring agents (example licorice candy) or acidity regulator. High purity and safe for human consumption
It has a different regulatory standards depending on the country

4 Analytical grade Ammonium chloride
Very high purity used for laboratory and research purposes Suitable for chemical analysis and experiments
Usually comes with the certificate of analysis

Contraindications

Severe liver or kidney disease. Metabolic or respiratory acidosis. Patients on sodium Restricted diet. Hypersensitivity to ammonium salt.

Precautions

Caution in children under two years (risk of mucus accumulation or choking). Use carefully in asthma or COPD-excessive secrets may worsen symptoms. Avoid overdose-higher doses may cause toxicity.
Monitor inpatient with electrolyte imbalances.

Drug interaction

May interact with urinary alkalinizes example sodium bicarbonate Use with alongside diuretics may affect electrolyte balance
No significant interactions in standard low dose expectorant use.

Storage

Store at room temperature 15 to 25 degrees Celsius Keep tightly close

Clinical notes

Always taken with blood to help thin mucus.
Commonly used in multi-ingredient cough syrups, often with antihistamines, bronchodilators, or decongestants. Not effective alone for chronic cough or severe mucus retention.
Avoid prolonged or unsupervised use, especially in young children.

Summary table

Parameters	Details
Drug class	Expectorant
Mechanism	Increase Bronchial secretion
Form	Syrup (often in combinations)
Pediatric use	Common in 2+ (years age-appropriate dosing)
Side effects	GI upset, nausea, rare CNS Symptoms
Use infants	Not recommended under 2 years
Pregnancy / Lactation	Caution advice L.T.D. data

Clinical case example

A 7-year-old child presents with a wet, chest cough for 4 days, no fever, normal appetite and activity chest is clear the doctor prescribes cough syrup containing ammonium chloride 5MG + diphenhydramine sodium citrate 5MG every 8 hours for five days along with the hydration saline nasal drops at follow up, the child shows reduced mucus thickness and cough frequency

Case study

Public Alert-Stop Use Notice
Stop Use Notice Regarding Coldrif Syrup (Batch No. SR-13) Due to Toxic Adulteration
The Food and Drugs Administration, Maharashtra, has been alerted to reports of the tragic deaths of children in Madhya Pradesh and Rajasthan, Coldrif Syrup (Phenylephrine Hydrochloride, Chlorpheniramine Maleate Syrup), Batch No. SR-13, Mfg. Dt. May-2025, Exp. Dt. April-2027, manufactured by Sresan Pharma, Sunguvarchathiram, Kancheepuram District, Tamil Nadu, which has been allegedly adulterated with Diethylene Glycol (DEG), a toxic substance.
In view of this, all the licensee and public hereby instructed to immediately stop sale/distribution/use of Coldrif Syrup, Batch No. SR-13, if anybody is in possession, and report it to the local Drugs Control Authorities without delay.

The public may also report possession of the said drug directly to the Food and Drugs Administration, Maharashtra, through the toll-free number 1800222365 or by email to jchq.fda-mah@nic.in or ph.- 9892832289
FDA Maharashtra officials are coordinating with the DCA authorities of Tamil Nadu, where the manufacturer Sresan Pharma is located, to track the distribution of the said product batch to Maharashtra.

All Drugs Inspectors and Assistant Commissioners have been instructed to immediately alert retailers, wholesalers, and hospitals to freeze any stocks of the said product batch if available in the market.



Coldrif Cough Syrup Banned After Child DeathsThe Coldrif syrup (by Sresan Pharma) is banned after child deaths in MP C Rajasthan due to toxic chemical (DEG) contamination. States have recalled affected batches, and parents are warned not to give cough syrups to young children





Conclusion

Megabytes. Aspetar's. and bracer adaptors pay Crocuta roles in the management to cough, targeting deterrent aspects of rotatory condones, Mucolytics help equally and reduce the viscosity of mucus, expectorants promote mucus production and expulsion. while bronchodilators dilate the Aiwa's to improve breathing Combining these medications may be necessary to address specific underlying causes or symptoms of cough, but I should always be done under the supervision.

Reference

1. Waner A, Salathe M, O'Riordan TG, Mucociliary clearance in the airways. Am J Respir Crit Care Med 1996; 154: 1868- 1902.
2. Rubin BK. The pharmacologic approach ta airway clearance: mucoactive agents. Respir Care 2002; 47: 818- 822.
3. King M, Rubin BK. Pharmacological
4. approaches to discovery and development of new mucolytic agents. Adv Drug Deliv Rev 2002; 54: 1475-1490.
5. Rogers DF, Barnes PJ. Treatment of airway mucus hypersecretion. Ann Med 2006; 38: 116-125
6. ~ Rubin BK, van der Schaans CP, eds. Therapy for Mucus Clearance Disorders. C. L'Enfant, executive editor. Biology of the Lung Series. New York, Marcel Dekker, 2004
7. Lopez-Vidrio MT. Airway mucus: production and composition. Chest 1981; 80: 799-804.
8. Kallner M, Marom Z, Paotow C, et al Human respiratory mucus. J Allergy Clair Immunol 1984; 73:318-323.
9. Braga PC, Zimin I, Allegra L
10. Classification of agents that act on bronchial mucus. In: Braga PC, Allegra L, eds. Drugs in Bronchial Mycology. New York, Raven Press, 1989, pp. 59-67
11. R Balsam, L Lanata, GC Egan European Respiratory Review 19(116)
12. Kristin Patzwaldt, Salvador Castaneda-Vega, Neural regeneration research 10(11),2.345-2346 2024.
13. Kick, Joss, F, W, shriven. C Beseechers, gusseting 3,536,713, October 27, 1970, assigned to Ingelheim G, m, b, H.
14. Yuta Baraniak JN; therapeutic approaches to mucus hypersecretion, cur allergy asthma rep 2005 may; 5(3);243-51.
15. Elisabetta pace, ISA Cervera, Donato laced onia, Gregorian Paone. Alessandro San dizi Zamparelli pharmaceutic 14(6), 1261,2022.
16. Hooper C, Calvert J; (carbonitride) in the management of chronic obstructive pulmonary diseases J corn obstruct pullman dis.2008 3(4); 659-69.

17. Tiruvannamalai R, Conrad CK, Bottiglieri T, et al. High-dose oral N-acetylcysteine, a glutathione prodrug, modulates inflammation in cystic fibrosis. Proc Natl Accad Sci USA 2006; 103: 4628-4633
18. Daulatabad N, Fischer P Aulbach B, et al. A phase l| study on safety and efficacy of high- dose N- acetylcysteine in patients with cystic fibrosis. Eury J Med Res 2009; 14: 352-358.
19. Venhuizen PN. Antioxidant properties of N-acetylcysteine: their relevance in relation to chronic obstructive pulmonary disease. Eury Respir J 2004; 23: 629-636.
20. Reichenberger F, Tamm M. N- Acetylcysteine in der Therapee der chromistan Bronchitis. [N-acetylcysteine in the therapy of chronic bronchitis). Pneumology 2002; 56: 793-797.
21. Gross NJ. Anticholinergic agents. In: Leff AR, ed. Pulmonary and Critical Care Pharmacology and Therapeutics. New York, McGraw-Hill, 1996; pp. 535-552.
22. Arai N, Kondo M, Izumo T, et al. Inhibition of neutrophil elastase-induced goblet cell metaplasia by tiotropium in mice. Eury Respir 」 2010; 35: 1164-1171.
23. Ramnarine Sly, Haddad EB, Khawaja AM, et al. On muscarinic control of neurogenic mucus secretion in ferret trachea. J Physio 1996; 494: 577-586.
24. Ishihara H, Shimura S, Satoh M, et al. Muscarinic receptor subtypes in feline tracheal submucosal gland secretion. Am J Physio 1992; 262: 223L-228L.
25. Olivier KN, Bennett WD, Honaker KW, et al. Acute safety and effects on mucociliary clearance of aerosolized uridine 5'-triphosphate +/- amiloride in normal human adults. Am J Respir Crit Care Med 19%; 154: 217-223.
26. Jail, A hoar, James F Donohue Selwyn Sangeetha chronic obstructive pulmonary diseases journal of the COPD foundation 6(4), 341-51.
27. Kellerman D, Rossi Mospan A, Engels J, et al. Damfoos: a review of studies with inhaled P2Y2 agonists that led to phase 3. Plum Pharmacal Ther 2008; 21: 600-607.
28. Kellerman D, Rossi Mospan A, Engels J, et al. Damfoos: a review of studies with inhaled P2Y2 agonists that led to phase 3. Plum Pharmacal Ther 2008; 21: 600-607.
29. Rogers DF. Mucoactive drugs for asthma and COPD: any place in therapy? Expert Opine Investing Drugs 2002; 11: 15-35.
30. " Hafez R, Degand P, Roussel P, et al. Biochemical mechanism of action of cysteine derivatives on bronchial mucus. Poupon Coeur 1970; 26: 81-90.
31. Zheng JP, Kang J, Huang SG, et al. Effect of carbocisteine on acute exacerbation of chronic obstructive pulmonary disease (PEACE Study): a randomized placebo- controlled study. Lancet 2008; 371: 2013- 2018.
32. Allegra L, Cordaro CI, Grassi C. Prevention of acute exacerbations of chronic obstructive bronchitis with carbocysteine lysine salt monohydrate: a multicenter, double-blind, placebo-controlled trial. Respiration 1996; 63: 174-180.
33. Yuta A, Baraniak JN. Therapeutic approaches to airway hypersecretion. Curr Allergy Asthma Rep 2005; 5: 243-251.
34. Zimin I. Respiratory Pharmacology and Therapeutics. Philadelphia, WB Saunders, 1988.
35. Donaldson SH, Bennett WD, Zeman KL, et al. Mucus clearance and lung in cystic fibrosis with hypertonic saline. N Engl J Med 2006; 354: 241-250.
36. Pucelle E, Girard F Polu JM, et al. Effect of the mucoregulator S-carboxy-methyl- cysteine in patients with chronic bronchitis. Eura 」 Clin Pharmakoi| 1978; 14: 177-184.
37. Colombo B, Tesconi P, Daffynition L, et al, Stimulation of Cl secretion by the mucoactive drug S-carboxy-methylcysteinelysine salt in the isolated rabbit trachea. Eura Respir J 1994; 7: 1622- 1628.
38. Asti C, Melillo G, Caselli GF, et al, Effectiveness of carbocysteine lysine salt monohydrate on models of airway inflammation and hyperresponsiveness pharmocol Res 1995; 31: 387-392.
39. Yeates DB, Cohen VR, Davis AL, et al. Effect of glyceryl guaiacol ate on bronchial clearance in patients with chronic bronchitis. Am Rev Respir Dis 1977; 115: 182.
40. Sisson JH, Yonkers AJ, Waldman RH. Effects of guaifenesin on nasal mucociliary clearance and ciliary beat frequency in healthy volunteers. Chest 1995; 107: 747- 751.
41. Sisson JH, Yonkers AJ, Waldman RH. Effects of guaifenesin on nasal mucociliary clearance and ciliary beat frequency in healthy volunteers. Chest 1995; 107: 747- 751.
42. Fiocchi A Grasso U, Zuccotti G, et al. Diiodo| treatment for bronchopulmonary diseases in the pediatric age group: a double-

blind controlled clinical trial versus placebo. J Int Med Res 1988; 16: 31-38.

43. Meltzer EO. Intranasal anticholinergic therapy of rhinorrhea. J Allergy Clin Immunol 1992; 90: 1055-1064.

44. Rahman I. Antioxidant therapeutic advances in COPD. Ther Adv Respir Dis 2008; 2: 351-74.

45. Pena LR, Hill DB, McClain CJ. Treatment with glutathione precursor decreases cytokine activity. JPEN J Parented Enteral Nutra 1999; 23:1-6.

46. Macio A, Mudede C, Panzone F, et al. Carbocysteine: clinical experience and new perspectives in the treatment of chronic inflammatory diseases. Expert opine Pharmacotherapy 2009; 10: 693-703.

47. Petty TL. The national mucolytic study: results of a randomized, double blind, placebo-controlled study of iodinated glycerol in chronic obstructive bronchitis. Chest 1990: 98: 1309-1310.